Multidisciplinary Management of Radiation-Induced Salivary Gland Carcinomas in the Modern Radiotherapy Era.

Published on Dec 14, 2020in Cancers6.126
· DOI :10.3390/CANCERS12123769
Domenico Attilio Romanello3
Estimated H-index: 3
,
Zulfiyya Imamguliyeva + 13 AuthorsEster Orlandi22
Estimated H-index: 22
Sources
Abstract
Clinical data of ri-SGCs patients treated between 2015 and 2019 at a tertiary cancer center and a national hadron therapy facility were reviewed. Latent time (LT) from first RT to ri-SGCs diagnosis, overall (OS), and disease-free survival (DFS) were assessed. Thirteen patients developed 14 ri-SGCs (one patient had 2 synchronous ri-SCGs), after a median LT of 23 years (range 16–34). Parotid was the primary site in 8 cases (57%) and salivary duct carcinoma was the most frequent histotype (29%). Nine patients (69%) underwent surgery (Sx). Among them, 4 patients (31%) underwent Sx alone, 5 received post-operative treatments: 3 (23%) photon-based (X) reRT, one (8%) protons and carbon ions, one (8%) carbon ions only. One patient (8%) received definitive XRT. The remaining 3 patients (23%) received androgen deprivation therapy. With a median follow-up of 48 months (range 24–72), median OS and PFS were 74 and 24 months, respectively. In the subgroup of AR+ ri-SGCs, median PFS and OS were 12 and 74 months, respectively. Given the rarity of ri-SGCs, this work adds further knowledge to the paucity of literature. The management of these malignancies is extremely complex requiring a multidisciplinary treatment approach.
References53
Newest
#1Kenneth Jensen (Aarhus University Hospital)H-Index: 16
#2Jeppe Friborg (Copenhagen University Hospital)H-Index: 20
Last. Cai Grau (Aarhus University Hospital)H-Index: 60
view all 18 authors...
4 CitationsSource
#1David G. Pfister (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 81
#2Sharon A. SpencerH-Index: 53
Last. Susan Darlow (National Comprehensive Cancer Network)H-Index: 22
view all 37 authors...
Author(s): Pfister, David G; Spencer, Sharon; Brizel, David M; Burtness, Barbara; Busse, Paul M; Caudell, Jimmy J; Cmelak, Anthony J; Colevas, A Dimitrios; Dunphy, Frank; Eisele, David W; Gilbert, Jill; Gillison, Maura L; Haddad, Robert I; Haughey, Bruce H; Hicks, Wesley L; Hitchcock, Ying J; Jimeno, Antonio; Kies, Merrill S; Lydiatt, William M; Maghami, Ellie; Martins, Renato; McCaffrey, Thomas; Mell, Loren K; Mittal, Bharat B; Pinto, Harlan A; Ridge, John A; Rodriguez, Cristina P; Samant, Sand...
54 CitationsSource
#1Laura D. LocatiH-Index: 31
#2Donata GalbiatiH-Index: 5
Last. Lisa Licitra (University of Milan)H-Index: 67
view all 17 authors...
BACKGROUND: The treatment of patients with recurrent and/or metastatic (R/M) salivary gland adenoid cystic carcinoma (ACC) remains an unmet need. METHODS: Patients with R/M disease with a history of clinical or symptomatic disease progression within 6 months and a maximum of 1 previous line of chemotherapy or a multiple kinase inhibitor received oral lenvatinib at a dose of 24 mg/day. The primary endpoint was the objective response rate; secondary endpoints included quality of life (QOL) (accord...
6 CitationsSource
#1Barbara VischioniH-Index: 14
#2B. Dhanireddy (Albert B. Chandler Hospital)H-Index: 1
Last. Roberto Orecchia (IEO: European Institute of Oncology)H-Index: 71
view all 17 authors...
Abstract Aims To report oncologic and functional outcomes in terms of tumor control and toxicity of carbon ion radiotherapy (CIRT) in reirradiation setting for recurrent salivary gland tumors at CNAO. Methods From November 2013 to September 2016, 51 consecutive patients with inoperable recurrent salivary gland tumors were retreated with CIRT in the frame of the phase II protocol CNAO S14/2012C for recurrent head and neck tumors. Results Majority of pts (74.5%) had adenoid cystic carcinoma, mainl...
5 CitationsSource
#1Assaf Moore (TAU: Tel Aviv University)H-Index: 8
#2Yael Bar (TAU: Tel Aviv University)H-Index: 5
Last. Aron Popovtzer (TAU: Tel Aviv University)H-Index: 21
view all 11 authors...
BACKGROUND: Salivary gland cancers (SGCs) are rare. The approach to metastatic patients is histology-dependent. There is little evidence on whether next-generation sequencing (NGS) findings translate to tumor control in SGCs. METHODS: We analyzed all patients with histologically confirmed SGC who underwent NGS. RESULTS: Twenty-seven patients were identified, 14 (51.8%) had targetable findings in NGS: 5 ERBB2 amplifications, 3 PIK3CA mutations, 2 RUNX1 mutations, 1 TRIM33-RET fusion, 1 FGFR3-TACC...
3 CitationsSource
#1Masato Nakaguro (Nagoya University)H-Index: 10
#2Makoto Urano (Fujita Health University)H-Index: 13
Last. Toshitaka Nagao (TMU: Tokyo Medical University)H-Index: 28
view all 19 authors...
AIMS: Minor salivary gland tumours showing a predominant papillary-cystic structure are rare, and constitute a mixture of various types of neoplasm; thus, the histopathological assessment of these tumours poses a significant diagnostic challenge. We aimed to delineate the histological characteristics of these tumours and further mutational aspects with a particular focus on sialadenoma papilliferum (SP) and intraductal papillary mucinous neoplasm (IPMN). METHODS AND RESULTS: We retrieved 28 papi...
13 CitationsSource
BACKGROUND: To report the long-term outcome of patients undergoing re-irradiation (re-RT) for a recurrent or second primary head and neck cancer (RSPHNCs) in seven Italian tertiary centers, while testing the Multi-Institution Reirradation (MIRI) recursive partitioning analysis (RPA) recently published. METHODS: We retrospectively analyzed 159 patients. Prognostic factors for overall survival (OS) selected by a random forest model were included in a multivariable Cox analysis. To externally valid...
5 CitationsSource
#1Kazuhiko Hayashi (Osaka University)H-Index: 12
#1Kazuhiko Hayashi (NIRS: National Institute of Radiological Sciences)H-Index: 11
Last. Tadashi Kamada (NIRS: National Institute of Radiological Sciences)H-Index: 50
view all 7 authors...
Abstract Background and purpose Locoregional recurrence after carbon-ion radiotherapy (CIRT) for primary head and neck malignancies, such as malignant mucosal melanoma, adenoid cystic carcinoma, and sarcoma, occurs occasionally. However, the treatment options are limited. We report on the toxicity and efficacy of re-irradiation using carbon ions for recurrent head and neck malignancies after CIRT. Materials and methods Data of 48 patients with recurrent head and neck malignancies treated with re...
8 CitationsSource
#1Alena Skálová (Charles University in Prague)H-Index: 33
#2Tomas Vanecek (Charles University in Prague)H-Index: 30
Last. Michal Michal (Charles University in Prague)H-Index: 68
view all 15 authors...
Intraductal carcinoma (IC) is the new World Health Organization designation for tumors previously called “low-grade cribriform cystadenocarcinoma” and “low-grade salivary duct carcinoma.” The relationship of IC to salivary duct carcinoma is controversial, but they now are considered to be distinct e
37 CitationsSource
#1Roger B. Cohen (UPenn: University of Pennsylvania)H-Index: 32
#2Jean Pierre DelordH-Index: 27
Last. Bhumsuk Keam (UPenn: University of Pennsylvania)H-Index: 1
view all 18 authors...
OBJECTIVES: Treatment options for patients with unresectable or metastatic salivary gland carcinoma (SGC) are limited. Safety and efficacy of pembrolizumab for SGC expressing programmed death ligand 1 (PD-L1) were explored. MATERIALS AND METHODS: A cohort of patients with advanced, PD-L1-positive SGC was enrolled in the nonrandomized, multicohort, phase Ib trial of pembrolizumab in patients with PD-L1-positive advanced solid tumors (KEYNOTE-028; NCT02054806). Key inclusion criteria included recu...
59 CitationsSource
Cited By0
Newest